AR109456A2 -
USE OF ET743 FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF A HUMAN PATIENT AFFECTED BY CANCER THROUGH COMBINATION THERAPY
- Google Patents
USE OF ET743 FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF A HUMAN PATIENT AFFECTED BY CANCER THROUGH COMBINATION THERAPY
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar SafiledCriticalPharma Mar Sa
Publication of AR109456A2publicationCriticalpatent/AR109456A2/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
Uso de ET743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación, involucrando la administración de ET743 y dexametasona.Use of ET743 for the preparation of a medicament for the treatment of a human patient affected by cancer by combination therapy, involving the administration of ET743 and dexamethasone.
ARP170101288A1999-05-132017-05-15
USE OF ET743 FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF A HUMAN PATIENT AFFECTED BY CANCER THROUGH COMBINATION THERAPY
AR109456A2
(en)
A COMPOSITION FOR THE TREATMENT OF EXTERNAL RETINA DISORDERS AND THE USE OF A GLUTAMATE ANTAGONIST FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF EXTERNAL RETINA DISORDERS
Ask the doctor. In your article on Alzheimer's disease (March, 1999), you mention" high doses of vitamin E" as helpful in slowing the progression of the condition. Specifically, what dose is recommended?